Publication: Homocysteine and restenosis after percutaneous coronary intervention
Issued Date
2001-12-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0037930331
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.84, No.SUPPL. 3 (2001)
Suggested Citation
Nithi Mahanonda, Wattana Leowattana, Charuwan Kangkagate, Pakorn Lolekha, Sasikant Pokum Homocysteine and restenosis after percutaneous coronary intervention. Journal of the Medical Association of Thailand. Vol.84, No.SUPPL. 3 (2001). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26639
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Homocysteine and restenosis after percutaneous coronary intervention
Other Contributor(s)
Abstract
Numerous clinical studies in Western and Asian countries suggest that individuals with elevated blood levels of homocysteine have an increased risk of atherosclerosis, myocardial infarction, cerebral infarction, and deep vein thrombosis. Homocysteine is also known to induce both atherogenic and thrombogenic mediators in cultured vascular cells so that homocysteine may influence the damage of endothelial cells, promote smooth muscle cell growth, induce atherogenic mediators' and thrombus formation after coronary angioplasty. The association between homocysteine and restenosis after percutaneous coronary intervention (PCI) has been discussed. In this study, the relationship between plasma homocysteine levels and restenosis after PCI to investigate whether plasma homocysteine levels may be a predictor of restenosis after PCI was examined. One hundred consecutive patients who underwent successful PCI were enrolled and plasma homocysteine level was measured in all patients prior to PCI. Plasma for homocysteine level was obtained in 99 of 100 patients who had angioplasty. The mean plasma homocysteine concentration in the enrolled patients was 13.61±6.04 μmol/L. The minimum and maximum of plasma homocysteine were 4.40 μmol/L and 50.00 μmol/L, respectively. In healthy subjects, the normal reference range of homocysteine level is 5-15 μmol/L However, recent data suggest that some patients may be at increased cardiovascular and cerebrovascular risk at levels as low as 12 μmol/L. For this reason, both cut off points of homocysteine level ≥ 15 μmol/L or ≥ 12 μmol/L to identify the high homocysteine level group were used. Of 99 patients, high homocysteine level (≥ 15 μmol/L) was established in 9 patients with restenosis versus 20 patients without restenosis. If the cut off point of homocysteine level ≥ 12 μmol/L was used, high homocysteine level was established in 14 patients with restenosis versus 39 patients without restenosis. From both cut off points of homocysteine level, there was no correlation between plasma homocysteine level and the restenosis group. (p>0.05).